NCT04197934View on ClinicalTrials.gov

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

PHASE1RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 20, 2019

Primary Completion Date

December 20, 2025

Study Completion Date

December 20, 2025

Conditions
Anaplastic Astrocytoma, IDH-WildtypeGlioblastoma, IDH-WildtypeMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the Central Nervous SystemStage IV Lung Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection - blood samples

Undergo collection of blood samples

PROCEDURE

Biospecimen Collection - CSF samples

Undergo collection of CSF samples

PROCEDURE

Computed Tomography

Undergo CT

DRUG

EGFR/EGFRvIII Inhibitor WSD0922-FU

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgical resection

Trial Locations (3)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

85259

RECRUITING

Mayo Clinic in Arizona, Scottsdale

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT04197934 - WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases | Biotech Hunter | Biotech Hunter